treatment of stage iv nsclc with high pd-l1 and atypical mutation - lung cancer onctalk 2022
Published 1 year ago • 35 plays • Length 2:18Download video MP4
Download video MP3
Similar videos
-
8:03
studies in anti-pd-l1 monotherapy for nsclc - lung cancer onctalk 2022
-
3:23
treatments algorithms for advanced nsclc - lung cancer onctalk 2022
-
7:35
current treatments for oligometastatic nsclc - lung cancer onctalk 2022
-
6:52
combination chemotherapy and immunotherapy for patients with high pd-l1 nsclc - 2022 program: lcvl
-
9:49
gracecast - treatment options for patients with nsclc and high tumor pd-l1 expression
-
6:56
gracecast - leading treatment options for patients with negative tumor pd-l1 nsclc with dr. stephen
-
4:40
ntrk nsclc: treatment options and side effects - targeted therapies in lung cancer 2023
-
4:02
treatment of egfr mutated nsclc - 2022 program: targeted therapies forum - english
-
2:35:24
onctalk 2020, connecting patients to the experts
-
2:02
progression on pembrolizumab: patient without actionable mutations & low pd-l1 - lung cancer onctalk
-
6:17
asco 2021 lung recap: amivantamab and mobocertinib for egfr exon 20
-
7:41
gracecast-113_lung-cancer_asco 2012 lc highlights: dr. neal on anti-pd-1 immunotherapy for nsclc
-
15:54
gracecast-075_lung-cancer_ccilc - optimal treatment for stage iiia n2 node-positive nsclc
-
14:59
gracecast-074_lung-cancer_ccilc - adjuvant therapy for smaller node-negative nsclc
-
15:53
gracecast-054_lung-cancer_socinski on advanced nsclc maintenance therapy q&a
-
13:00
stage 3a node-positive lung adenocarcinoma with alk rearrangement - case based panel discussions
-
6:20
oncogene-driven metastatic nsclc: frontline treatment & resistance mechanisms - onctalk 2022
-
21:33
optimal ngs platforms, how to interpret - grace targeted therapies in lung cancer patient forum 2021
-
9:26
gracecast - lcvl - which patients with advanced nsclc are good candidates for first line immunothera